Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)
  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: This medical device record is a PMA supplement. A supplement may have changed the device description/function or indication from that approved in the original PMA. Be sure to look at the original PMA record for more information.
 
DeviceVisuMax Femtosecond Laser
Generic NameFemtosecond laser system for refractive correction
ApplicantCarl Zeiss Meditec, Inc.
5160 Hacienda Drive
Dublin, CA 94568
PMA NumberP150040
Supplement NumberS003
Date Received03/23/2018
Decision Date10/04/2018
Product Code OTL 
Docket Number 18M-3842
Notice Date 10/25/2018
Advisory Committee Ophthalmic
Clinical TrialsNCT02430428
Supplement TypePanel Track
Supplement Reason Labeling Change - Indications/instructions/shelf life/tradename
Expedited Review Granted? No
Combination ProductNo
Approval Order Statement  
Approval for the VisuMax Femtosecond Laser. This device is indicated for use in small incision lenticule extraction (SMILE) for the reduction or elimination of myopia with or without astigmatism:1) For spherical refractive error (in minus cylinder format) from -1.00 diopters through -10.00 diopters;2) For cylinder from -0.75 diopters through -3.00 diopters; and3) When refraction spherical equivalent is no greater in magnitude than 10.00 diopters, in patients 22 years of age or older with documentation of stable manifest refraction over the past year as demonstrated by a change in sphere and cylinder of less than or equal to 0.50 D in magnitude.
Approval OrderApproval Order
SummarySummary of Safety and Effectiveness
LabelingLabeling
Labeling Part 2
Post-Approval StudyShow Report Schedule and Study Progress
-
-